>> I don't blame them for pursuing this [SPA] strategy. <<
katie: I would turn your statement around and say that I will blame any company which does not secure an SPA for a pivotal trial. And I probably will not invest in such a company.
The SPA is the greatest thing to come along in quite a while for investors in emerging-stage biotechs. It will now be easier for investors to separate the companies with excellent prospects (e.g. GENR) from the companies which are little more than hyped research projects at the expense of unsuspecting shareholders.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.